Zeltia continue strong growth

pharmafile | February 26, 2010 | News story | Sales and Marketing 2009 financials, PharmaMar, Yondelis, Zeltia 

Consolidated revenues at Spanish biopharmaceutical company Zeltia increased by 17% to 123.4 million euros enabling it to halve operating losses.

These were reduced by 43% to 21.2 million before interest and taxes, aided by a 53% jump in biopharmaceutical revenue that was primarily driven by Yondelis (trabectedin).

The drug, which racked up sales of 44 million euros, is marketed by Zeltia’s PharmaMar division and indicated for the treatment of a group of rare cancers called soft tissue sarcomas.

In November 2009 it was approved in Europe to treat ovarian cancer, an indication which this week received the backing of UK clinical and cost effectiveness body NICE.

Advertisement

Zeltia’s molecular diagnostics company Genomica increased its revenues by 37% to 7.3 million euro and, despite the effects of the adverse economic situation on consumer spending, revenues in the Consumer Chemicals division totaled 71.2 million euro, up 0.7%.

Related Content

shutter

Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population

Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with …

FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer

The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a …

The Gateway to Local Adoption Series

Latest content